Prescribing information

 

Prescribing information

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Below you can access the latest educational webinars organised by Novartis and hosted by experts in the field of MS and with a specific focus on SPMS with active disease. You will find full recordings, enabling you to listen to the webinars at a time that is convenient for you.

You will be required to register to watch the videos.

Video. Preview image of a clock and people looking towards the clock. Title of the video: Developing a MAYZENT (siponimod) patient pathway for your MS service.

Developing a MAYZENT (siponimod) patient pathway for your MS service

Watch Dr Wallace Brownlee and Ms Joela Mathews discuss the importance of DMT pathways and share the MAYZENT protocol for patients with SPMS with active disease, using specific patient cases to exemplify how the process can be implemented within local MS services.  

Watch

Video. Preview image of a clock and people looking towards the clock. Title of the video: When and how to switch eligible patients to MAYZENT (siponimod) – Real World Experience.

When & how to switch eligible patients to MAYZENT (siponimod) – Real World Experience

Watch Prof Christoph Kleinschnitz discuss when and how to switch eligible patients to MAYZENT. He shares his experience with MAYZENT so far, based on the patients in his clinic in Essen, Germany, and discusses a patient case study in more detail.

Watch

 

 

Video thumbnail. Title of the video: Redefining expectations in SPMS through innovation and advances in patient care.

Redefining expectations in SPMS through innovation and advances in patient care

Watch Dr Emma Tallantyre, Dr David Paling and Carmel Wilkinson discuss how advances in patient care are redefining expectations in SPMS from a patient, HCP, and MS service provider perspective, in this symposium from the ABN Virtual Meeting 2020.  

Watch

Video thumbnail. Title of the video: Identifying SPMS with active disease and how perceptions are evolving in the UK.

Identifying SPMS with active disease and how perceptions are evolving in the UK

Join Dr Martin Duddy in this symposium from the ABN Virtual Meeting 2020, as he provides key information on current diagnostic criteria and patterns in the UK, and how to overcome the challenges in defining SPMS with active disease, and highlights best practice through a case study.

Watch

 

Indication:

MAYZENT is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.1

ABN, Association of British Neurologists; DMT, disease-modifying therapy; HCP, healthcare professional; MS, multiple sclerosis; SPMS, secondary progressive multiple sclerosis.

Reference:

1. MAYZENT (siponimod) Summary of Product Characteristics.

Rate this content: 
Average: 5 (1 vote)
UK | August 2021 | 127652
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]